Nanosystem-Mediated Phototherapy–Chemodynamic Therapy: Synergistic Mechanisms and Translational Barriers in Precision Oncology
Key Insights
Global cancer (search) incidence reached approximately 20 million new cases and 9.7 million deaths in 2022, with projections of 35 million cases by 2050, underscoring the urgent need for safer and more effective anticancer strategies.
Chemodynamic therapy (CDT) exploits tumor microenvironment H₂O₂ and acidic pH to generate cytotoxic hydroxyl radicals via Fenton/Fenton-like reactions, but faces bottlenecks including insufficient H₂O₂, GSH-mediated ROS scavenging, and poor catalyst targeting.
Phototherapy (PDT/PTT) synergistically enhances CDT through thermodynamic acceleration of Fenton kinetics, GSH depletion, H₂O₂ self-supply, ECM degradation, and immunogenic cell death activation, creating multi-dimensional complementary antitumor effects.
The global cancer (search) burden continues to escalate at an alarming rate. In 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide, with Asia accounting for nearly half of the global burden. Driven by aging populations and accumulating risk factors, new cases are projected to increase by 77% to 35 million by 2050, particularly in low- and medium-human development index countries. Conventional treatments—including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy—improve patient survival but carry critical limitations: surgical risks of recurrence, radiotherapy-induced resistance and adjacent tissue damage, chemotherapy-associated systemic toxicity and multidrug resistance, and immunotherapy's low response rates with immune-related adverse events. These drawbacks have intensified the search for safer, more effective anticancer strategies.
Chemodynamic Therapy: Principles and Persistent Bottlenecks
Chemodynamic therapy (CDT), first conceptualized in 2016 by Bu and Shi's group with amorphous iron nanoparticles, leverages Fenton and Fenton-like reactions to convert endogenous hydrogen peroxide (H₂O₂) into highly cytotoxic hydroxyl radicals (•OH) specifically at tumor sites. Unlike phototherapy or radiotherapy, CDT requires no external energy input, bypassing tissue penetration limitations and systemic toxicity. The tumor microenvironment (TME)—with its weakly acidic pH (5.5–6.5), elevated H₂O₂ levels (approximately 100 μM–1 mM), and high glutathione (GSH) concentrations—provides natural prerequisites for tumor-selective cytotoxicity.
However, CDT faces four interconnected TME-imposed bottlenecks. Endogenous H₂O₂ levels, though higher than in normal tissues, remain far below the optimal Fenton reaction threshold (>10 mM), with spatial distribution highly uneven and rapid clearance by catalase and glutathione peroxidase. The mildly acidic TME (pH 6.5–7.0) deviates substantially from the optimal Fenton pH (~3.0), triggering Fe³⁺ hydrolysis into inert iron hydroxide precipitates and shifting reaction pathways toward less toxic high-valent iron species (Fe(IV)=O). Intracellular GSH concentrations (1–10 mM, over fourfold higher than normal tissues) scavenge •OH at a rate constant of approximately 1.3×10¹⁰ M⁻¹s⁻¹, severely limiting effective radical diffusion. Tumor hypoxia further compromises CDT through HIF-1α (search)-mediated metabolic reprogramming that decreases endogenous H₂O₂ accumulation, upregulates GSH-related genes, and impairs catalyst delivery to deep tumor regions.
Beyond TME constraints, CDT catalysts suffer from low catalytic activity due to sluggish Fe³⁺/Fe²⁺ regeneration, poor tumor-targeting ability with predominant reticuloendothelial system accumulation in liver and spleen, and unresolved biocompatibility concerns including chronic inflammation and potential secondary tumor risks from prolonged metal retention.
Phototherapy-Enhanced CDT: Multi-Level Synergistic Mechanisms
Photodynamic therapy (PDT) and photothermal therapy (PTT) have emerged as powerful partners to overcome CDT limitations through complementary mechanisms spanning thermodynamics, substrate supply, antioxidant defense disruption, and immune activation.
PDT employs photosensitizers activated by specific-wavelength light (650–850 nm) to generate reactive oxygen species (ROS) via Type I (electron transfer) or Type II (energy transfer) reactions. The PDT-CDT synergy operates through four interconnected pathways: ROS cascade amplification, where PDT-generated singlet oxygen (¹O₂) and superoxide anion complement CDT-produced •OH, while certain nanomaterials mimic glucose oxidase activity to generate H₂O₂ and gluconic acid; GSH depletion via both Fenton reactions and PDT-mediated oxidation of GSH to GSSG, synergistically inactivating GPX4 (search) and overcoming ferroptosis resistance; microenvironment acidification through PDT-induced glycolytic shift and lactic acid accumulation, optimizing Fenton reaction pH; and synergistic antitumor immunity activation, where PDT-induced immunogenic cell death (ICD) releases damage-associated molecular patterns (DAMPs) including calreticulin, ATP, and HMGB1, while CDT attenuates immunosuppressive factors such as IL-10 and TGF-β.
PTT-CDT synergy centers on thermodynamic enhancement: localized hyperthermia (42–55 °C) exponentially accelerates Fenton kinetics following the Arrhenius law, increasing •OH generation rate constants. PTT simultaneously supplements H₂O₂ through enhanced glucose oxidase activity and improved microvascular oxygenation, depletes GSH via thermal oxidation while disrupting GSH regeneration kinetics, and degrades extracellular matrix (ECM) components to improve deep tumor penetration of catalysts. Critically, CDT-generated •OH disrupts HSP70 (search)/90-mediated cytoprotection, lowering the thermal tolerance threshold and enabling effective cell killing at mild temperatures—a chemical sensitization strategy that replaces physical heating.
The PDT-PTT-CDT trimodal combination achieves sustained oxidative suppression beyond the irradiation window. While PDT and PTT efficacy decays once light ceases, CDT continuously generates •OH for hours post-irradiation, preventing tumor cell repair and blocking recurrence. Cooperative GSH depletion through thermal oxidation, photodynamic oxidation, and Fenton consumption collectively dismantles antioxidant defenses. The three modalities converge on multiple cell death pathways—apoptosis via the mitochondrial pathway, ferroptosis through amplified lipid peroxidation and GPX4 (search) inactivation—preventing adaptive escape through any single resistance mechanism.
Nanosystem Evolution: From Prototypes to Intelligent Platforms
Multifunctional nanoplatforms have evolved through progressive development stages. Early PDT-CDT prototypes such as Fe₃O₄@Cu-TCPP established photoelectron-mediated catalytic nanoplatforms where photoinduced electrons accelerate Fe²⁺/Fe³⁺ cycling. Subsequent generations incorporated hypoxia-modulating modules (PCN-224@Co₃O₄-HA), acid-degradable MOF architectures (MIL-101(Fe)@TCPP), and biomimetic cascade bioreactors (Ce6/GOx@ZIF-8/PDA@MnO₂) enabling H₂O₂ self-supply and GSH depletion.
PTT-CDT systems have progressed from plasmonic Au@Cu₂₋ₓSe heterostructures to sophisticated enzyme-cascaded bioreactors such as Fe@HRP-ABTS/GOx nanodots, where intracellular glucose oxidase oxidizes glucose for self-supplied H₂O₂, horseradish peroxidase converts oxidized ABTS for photothermal conversion, and Fe-mediated Fenton reactions produce •OH while depleting GSH. Polydopamine-based platforms (PDA@Fe, Fe-PDA nanozymes) have gained prominence for their biocompatibility, broadband photothermal properties, and cooperative GSH depletion capabilities.
Trimodal PDT-PTT-CDT nanosystems—including FeWOx-PEG-RGD, FePtMn-Ce6/FA, and GOx@PCoS—integrate oxygen-dependent ROS generation, NIR-triggered hyperthermia, and self-sustaining Fenton catalysis. These platforms achieve mutual substrate supplementation, TME optimization, and multi-dimensional oxidative-thermal synergism.
Translational Barriers and Unresolved Challenges
Despite extensive preclinical validation in murine models, clinical translation of phototherapy-CDT combinatorial nanosystems remains substantially lagging. Only a limited number of phototherapeutic nanomedicines have gained regulatory approval: Photofrin® (FDA-approved since 1995), Ameluz®, and the most advanced PTT platform AuroShell (search)® (completed Phase I trials). This stark preclinical-clinical disparity highlights formidable barriers.
Tumor heterogeneity fundamentally compromises therapeutic consistency. Intratumoral variations in H₂O₂ concentration, pH, and GSH content create vastly different biochemical milieus rarely incorporated into nanoplatform design. Most studies selectively employ tumor models favoring specific nanocatalyst performance rather than validating across clinically relevant phenotypes.
Light penetration constraints are systematically underestimated. The vast majority of nanosystems are validated in shallow subcutaneous tumor models with optical paths of only millimeters. Clinically relevant solid tumors—particularly pancreatic ductal adenocarcinoma and glioblastoma—typically exceed 3–5 cm in depth, where NIR-I light intensity attenuates to less than 10% of incident dose. Although NIR-II materials (900–1880 nm) offer deeper tissue penetration, their inherently lower quantum yields and photothermal conversion efficiencies substantially limit this advantage.
Long-term metal-associated biosafety risks remain insufficiently characterized. Conventional biodistribution assessments typically terminate at 14–30 days post-injection, failing to capture chronic toxicities such as iron overload-induced systemic ferroptosis, copper-mediated hepatotoxicity, and manganese-induced dysregulation of dopaminergic signaling. Multi-metal toxicity synergies—where combined iron, copper, manganese, cobalt, or platinum in single nanosystems trigger unknown interactions—have largely not been explored.
Poor batch-to-batch reproducibility constrains industrial translation. Reported synthesis protocols exhibit substantial inter-laboratory variability, with hydrodynamic diameter deviations exceeding 30%, polydispersity index values exceeding 0.25, and relative standard deviations of drug loading content exceeding 20%. For trimodal platforms containing four or more functional components, manufacturing complexity increases exponentially, and most are no longer commercially feasible from a chemistry, manufacturing, and control (CMC) perspective.
Regulatory classification presents significant challenges. As diagnostic and therapeutic mixed entities with multiple active components, phototherapy-CDT nanosystems cannot follow existing regulatory frameworks for small-molecule drugs, biological products, or medical devices, resulting in an extremely uncertain clinical approval pathway. Harmonized guidelines for raw material qualification, in vitro toxicity assessment, in vivo biodistribution evaluation, and clinical trial approval criteria remain absent.
Future Directions
Emerging research directions include establishing unified evaluation criteria for nano-PDT/CDT systems, advancing NIR-II deep-tissue phototherapy with improved quantum yields, developing scalable manufacturing strategies including microfluidic synthesis for kilogram-scale production, and integrating artificial intelligence-assisted design for personalized treatment optimization. The selection of optimal nanosystems should be personalized based on specific tumor phenotypes, treatment plans, and clinical translation requirements, as no single nanosystem can achieve universal advantages in tumor treatment.